An ALS treatment wave is approaching, and this biotech CEO is ready to surf

Since Arun Swaminathan took over the helm as CEO of Coya Therapeutics late last year, the Houston-based biotech has been on solid financial ground. With a recent $10 million private placement investment, Coya is positioned with a cash runway to last through 2026. Plus, a commercialization partnership established in 2023 with Dr. Reddy’s for its lead candidate in amyotrophic lateral sclerosis meant Coya had a path to market with less financial pressure — a happy feat for a dealmaker like Swaminathan.